The Indian government is poised to overhaul Schedule H of its drug regulatory framework, addressing escalating concerns over antimicrobial resistance (AMR) linked to self-medication and the unchecked sale of antibiotics without prescriptions. Insights from a government official indicate that the impending changes aim to enhance public health by regulating the retail sale of medications deemed necessary for treating infectious diseases.
Currently, Schedule H contains about 536 drugs, which cannot be sold without a doctor’s prescription. The proposed revisions not only seek to incorporate newer medicines and formulations into this list but also respond to the growing issue of irrational drug use. The official, who spoke on condition of anonymity, emphasized the need for suitable reforms to combat the misuse of antimicrobials, which include antibiotics, antivirals, antifungals, and antiparasitics.
In 2022, the Ministry of Health appointed a high-level expert committee to evaluate and recommend comprehensive changes to Schedule H. This review aims to align India’s drug regulations with global best practices while addressing specific domestic health needs. Proposed additions to Schedule H include essential medications like remdesivir, dexamethasone, favipiravir, ivermectin, and mebrofenin, reflecting an evolving landscape of treatment options.
The committee meticulously assessed the existing regulatory landscape, noting that many drugs not categorized under Schedule G, H, H1, or X are routinely available without a registered medical practitioner’s oversight, which raises significant public health concerns. The documents reviewed suggest that numerous drugs for conditions like diabetes, tuberculosis, and cardiovascular diseases should also be categorized under Schedule H to ensure stricter enforcement regarding their use.
The expert committee underscores the importance of regular updates to Schedule H, highlighting that many drugs currently under prescription need reevaluation based on contemporary medical practices and the ongoing fight against AMR. They noted that misuse or overuse of these essential medicines can exacerbate AMR, complicating treatment efforts for serious infections.
Significantly, the committee is recommending the inclusion of over 700 additional drugs to Schedule H. These would cover a diverse range of categories, including cardiovascular, neurological, respiratory, anesthetic, antiemetic, and immunological drugs, among others. Each proposed category aims to bridge gaps in the existing regulatory framework, ensuring patient safety and effective treatment pathways.
Reviewing Schedule G, the committee found that while these drugs caution against use without medical oversight, the lack of explicit requirements for registered medical practitioner prescriptions in the past poses a risk. Unlike Schedule H, Schedule G’s regulatory measures have not mandated the same level of scrutiny for retail sales.
In conclusion, the planned updates to Schedule H represent a proactive step in safeguarding public health by tightening regulations around the sale of critical medications. As the complexities of drug use evolve, so too must the frameworks governing them, ensuring that both healthcare professionals and patients can navigate these critical resources safely and effectively.
Original Source: https://www.livemint.com/news/schedule-h-prescription-medicines-drug-dcgi-health-medicare-11749029495262.html
Category :
Tags:
Publish Date: 2025-06-04 18:44:00
